What Telehealth Providers Need to Know About Compounded Medications

Telehealth and compounded therapy fit together well — cash-pay, periodic rather than continuous contact, lab work drawn locally anywhere. But remote prescribing introduces constraints an in-person practice never encounters, and most of them surface as a failed fill rather than as a warning.

This is the clinical and regulatory side for prescribers. For platform partnership logistics, see our telehealth partnership program.

Licensure Runs on Two Tracks

This is the point that causes the most failed orders.

Your license must cover the state where the patient is located at the time of the encounter — not where you are, not where your employer is.

The pharmacy's license must separately cover that same state. A pharmacy needs a non-resident license in every state it ships into.

Both must be true. Practices frequently confirm one and assume the other, then discover the gap when a prescription cannot be filled — usually after the patient has paid.

Practical consequences: a patient who moves may need to be transferred; a patient treated while travelling may create a state-of-encounter question worth confirming in advance; and a platform advertising nationwide coverage needs both tracks covered in all fifty states.

Controlled Substances Are a Separate Regime

Most compounded peptides are not controlled substances, so the additional federal rules generally do not apply.

Testosterone is Schedule III. Remote prescribing of controlled substances is governed by federal rules that have changed repeatedly since 2020 and remain subject to change. If you prescribe testosterone remotely, you need a current compliance position — not one you established three years ago.

EPCS requirements also apply, and your e-prescribe platform must be configured accordingly.

What You Cannot Do Remotely

Order office stock. 503A compounding requires a prescription for a named patient. Remote practices are almost always patient-specific by nature, so this rarely bites — but a platform planning in-office administration through affiliated clinics needs a 503B relationship.

Skip the objective baseline. Prescribing hormone or peptide therapy without labs is not an evaluation. Labs are drawn locally and results routed to you; there is no practical reason to omit them, and doing so is the defining characteristic of the operations giving telehealth prescribing a bad name.

Assume continuity of supply. Compounding status changes. A patient mid-protocol whose refill cannot be filled is a clinical problem you will hear about first.

Cold Chain Is Your Problem Too

Many compounded preparations — peptides especially — require temperature-controlled shipping. In an in-person practice, storage is under your control. In telehealth, the preparation travels to a home address.

Confirm the pharmacy uses validated cold-chain packaging with temperature indicators, and set patient expectations about receiving and storing it. A patient who leaves a shipment on a porch in July has a degraded preparation and no way to know.

Documentation That Holds Up

Remote encounters get scrutinized more than in-person ones. Worth recording:

• The state the patient was physically located in during the encounter
• The modality used, and that it was real-time interactive where required
• The clinical rationale, including any documented clinically significant difference supporting a compounded preparation
• Baseline objective data
• The monitoring plan and follow-up interval
• Informed consent covering off-label or non-FDA-approved status where applicable

That last point matters more in this category than most. Many compounded peptides are not FDA-approved for any indication, and patients should understand that explicitly.

Choosing a Pharmacy Partner for Remote Practice

Beyond the standard verification in our compliance checklist, remote practice adds:

• Non-resident licensure across every state you serve — verified, not asserted
• Direct-to-patient fulfillment with tracking
• Validated cold chain with temperature indicators
• Advance notice of compounding status changes
• A workable submission path from your prescribing workflow

Frequently Asked Questions

Can telehealth providers prescribe compounded medications?

Yes, where both your license and the pharmacy's non-resident license cover the state where the patient is located. Both are required, and confirming only one is the most common cause of a failed fill.

Do I need to be licensed in the patient's state?

Generally yes — licensure follows the patient's physical location at the time of the encounter, not the provider's location.

Can I prescribe testosterone via telehealth?

In many cases yes, but testosterone is Schedule III and remote controlled-substance prescribing is governed by federal rules that have changed several times since 2020. You need a current compliance position and EPCS-capable prescribing.

Do I still need lab work for remote patients?

Yes. Labs are drawn locally and results routed to you. Prescribing hormone or peptide therapy without an objective baseline is not an evaluation, regardless of modality.

What happens if my patient moves to another state?

Your license and the pharmacy's license must both cover the new state. Notify the practice before the move — continuity across state lines is not automatic.

How are temperature-sensitive preparations handled?

Through validated cold-chain shipping with insulated packaging and temperature indicators. Set patient expectations about promptly receiving and refrigerating shipments, since a preparation left outside can degrade without visible signs.